主 頁 > 新 聞 及 資 訊

新 聞 及 資 訊   The United States: Victoza (liraglutide [rDNA origin]) Injection: REMS - risk of thyroid C-cell tumors, acute pancreatitis (English Only)   Novo Nordisk reminded healthcare professionals of important safety information about Victoza (liraglutide [rDNA origin]) injection required in a Risk Evaluation and Mitigation Strategy (REMS). There is potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) associated with Victoza. It may also increase the risk of acute pancreatitis. Because of these risks, Victoza is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. Patients with thyroid nodules noted on physical examination or neck imaging obtained for other reasons should be referred to an endocrinologist for further evaluation. Although routine monitoring of serum calcitonin is of uncertain value in patients treated with Victoza, if serum calcitonin is measured and found to be elevated, the patient should be referred to an endocrinologist for further evaluation. Please refer to the following website in FDA for details: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htm In Hong Kong, the above product is not registered. Ends/Tuesday, June 14, 2011 Issued at HKT 12:30